Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-pseudotyped Retroviral Vectors Produced in Suspension and Serum-free Media

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2009 May 21

PMID 19453219

Citations 40

Authors

Karim Ghani

Xiuyan Wang

Pedro Otavio de Campos-Lima

Malgorzata Olszewska

Amine Kamen

Isabelle Riviere

Manuel Caruso

Affiliations

Soon will be listed here.

Abstract

Retroviral vectors derived from the Moloney murine leukemia virus have been used in successful and promising gene therapy clinical trials. However, platforms for their large-scale production must be further developed. As a proof of principle, we reported the generation of a packaging cell line that produces amphotropic retroviral vectors in suspension and serum-free medium (SFM). In the present study, we have constructed and characterized two retroviral packaging cell lines designed for gene transfer in hematopoietic cells. These cell lines grow in suspension and SFM, and produce high-titer RD114- and gibbon ape leukemia virus (GALV)-pseudotyped vectors for a 3-month culture period. Viral particles released are as robust during repeated freeze-thaw cycles and on thermal inactivation at 37 degrees C as their counterparts produced in cells cultured adherently with serum. We also show that RD114- and GALV-pseudotyped vectors produced in suspension and SFM efficiently transduce human lymphocytes and hematopoietic stem cells. As these retroviral packaging cell lines distinctively maintain high vector titers while growing in suspension and SFM, we conclude that these cell lines are uniquely suitable for large-scale clinical-grade vector production for late-phase clinical trials involving gene transfer into hematopoietic cells.

Citing Articles

A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells.

van der Schans J, Katsarou A, Kladis G, Bar C, Ramirez M, Themeli M J Genet Eng Biotechnol. 2024; 22(4):100446.

PMID: 39674638 PMC: 11629549. DOI: 10.1016/j.jgeb.2024.100446.

Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells.

Renner A, Stahringer A, Ruppel K, Fricke S, Koehl U, Schmiedel D Gene Ther. 2024; 31(7-8):378-390.

PMID: 38684788 PMC: 11257948. DOI: 10.1038/s41434-024-00454-0.

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.

Stock S, Fertig L, Gottschlich A, Dorr J, Markl F, Majed L Cancer Immunol Immunother. 2024; 73(6):100.

PMID: 38630291 PMC: 11024081. DOI: 10.1007/s00262-024-03688-4.

Mutation-specific CAR T cells as precision therapy for IGLV3-21 expressing high-risk chronic lymphocytic leukemia.

Markl F, Schultheiss C, Ali M, Chen S, Zintchenko M, Egli L Nat Commun. 2024; 15(1):993.

PMID: 38307904 PMC: 10837166. DOI: 10.1038/s41467-024-45378-w.

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.

Markl F, Benmebarek M, Keyl J, Cadilha B, Geiger M, Karches C J Immunother Cancer. 2023; 11(5).

PMID: 37208128 PMC: 10201273. DOI: 10.1136/jitc-2022-006436.

References

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003; 3(1):35-45. DOI: 10.1038/nrc971. View

Ciceri F, Bonini C, Gallo-Stampino C, Bordignon C . Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy. 2005; 7(2):144-9. DOI: 10.1080/14653240510018136. View

Merten O . State-of-the-art of the production of retroviral vectors. J Gene Med. 2004; 6 Suppl 1:S105-24. DOI: 10.1002/jgm.499. View

Appelbaum F . Haematopoietic cell transplantation as immunotherapy. Nature. 2001; 411(6835):385-9. DOI: 10.1038/35077251. View

Strang B, Ikeda Y, Cosset F, Collins M, Takeuchi Y . Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Ther. 2004; 11(7):591-8. DOI: 10.1038/sj.gt.3302189. View

Murphy A, Westwood J, Teng M, Moeller M, Darcy P, Kershaw M . Gene modification strategies to induce tumor immunity. Immunity. 2005; 22(4):403-14. DOI: 10.1016/j.immuni.2005.03.007. View

Sandrin V, Boson B, Salmon P, Gay W, Negre D, Le Grand R . Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood. 2002; 100(3):823-32. DOI: 10.1182/blood-2001-11-0042. View

Cavazzana-Calvo M, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288(5466):669-72. DOI: 10.1126/science.288.5466.669. View

Ghani K, Cottin S, Kamen A, Caruso M . Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media. Gene Ther. 2007; 14(24):1705-11. DOI: 10.1038/sj.gt.3303039. View

10.

Ghani K, Garnier A, Coelho H, Transfiguracion J, Trudel P, Kamen A . Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor. Biotechnol Bioeng. 2006; 95(4):653-60. DOI: 10.1002/bit.20947. View

11.

Miller A, Garcia J, von Suhr N, Lynch C, Wilson C, Eiden M . Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol. 1991; 65(5):2220-4. PMC: 240569. DOI: 10.1128/JVI.65.5.2220-2224.1991. View

12.

Arai T, Takada M, Ui M, Iba H . Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts. Virology. 1999; 260(1):109-15. DOI: 10.1006/viro.1999.9773. View

13.

Onodera M, Nelson D, Yachie A, Jagadeesh G, Bunnell B, Morgan R . Development of improved adenosine deaminase retroviral vectors. J Virol. 1998; 72(3):1769-74. PMC: 109465. DOI: 10.1128/JVI.72.3.1769-1774.1998. View

14.

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

15.

Seppen J, Barry S, Lam G, Ramesh N, Osborne W . Retroviral preparations derived from PA317 packaging cells contain inhibitors that copurify with viral particles and are devoid of viral vector RNA. Hum Gene Ther. 2000; 11(5):771-5. DOI: 10.1089/10430340050015662. View

16.

Qiao J, Roy V, Girard M, Caruso M . High translation efficiency is mediated by the encephalomyocarditis virus internal ribosomal entry sites if the natural sequence surrounding the eleventh AUG is retained. Hum Gene Ther. 2002; 13(7):881-7. DOI: 10.1089/10430340252899046. View

17.

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

18.

Gallardo H, Tan C, Ory D, Sadelain M . Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood. 1997; 90(3):952-7. View

19.

Budak-Alpdogan T, Przybylowski M, Gonen M, Sadelain M, Bertino J, Riviere I . Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. Hum Gene Ther. 2006; 17(7):780-94. DOI: 10.1089/hum.2006.17.780. View

20.

Bonini C, Bondanza A, Perna S, Kaneko S, Traversari C, Ciceri F . The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther. 2007; 15(7):1248-52. DOI: 10.1038/sj.mt.6300190. View